ClinicalTrials.gg
CompletedNCT04804514Updated Feb 26, 2025

Evaluation of the Safety and Tolerability of KH001 in Dentin Hypersensitivity Patients

A Phase 1/2 interventional study of KH001 and Placebo in Dentin Sensitivity, sponsored by HysensBio Co., Ltd. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-02-26.

Sponsored by HysensBio Co., Ltd · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
19 Years to 65 Years
Sex
All
01

Study summary

This is a phase 1/2a study in dentin hypersensitivity patients to assess the safety, tolerability, efficacy and pharmacokinetics of single and multiple doses of KH001.

02

Conditions studied

  • Dentin Sensitivity

Keywords

  • Dentin regeneration
  • Hypersensitivity
  • Sensitivity
  • Tooth sensitivity
03

In context

Dentin Sensitivity

290 studies on the registry are indexed under Dentin Sensitivity; 48 are open to participants now.

This study's enrollment of 40 is below the median of 60 across 281 interventional studies indexed under Dentin Sensitivity.

Browse Dentin Sensitivity studies →

Lead sponsor

HysensBio Co., Ltd is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

[Inclusion criteria]

  1. Subjects must be fully aware of the purpose and the content of the study, and the characteristics of the Product to sign written consent of their free will to take part in the study;
  2. Subjects having at least 20 natural teeth and two teeth that could be assessed
  3. Subjects is diagnosed with dentin , has experienced dental symptoms of two or more teeth

[Exclusion criteria]

  1. Subjects is allergic to the active substance or other used in the Investigational Product
  2. Subjects has any history of allergy, such as drug allergy, asthma, eczema, or anaphylaxis
  3. Subjects has any disease related to dentin hypersensitivity
  4. Subjects taking anti-inflammatory analgesic drugs
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    KH001

    The study consists of sequential dosing cohorts, 8 subjects per cohort will be administered KH001 or placebo.

    Drug: KH001

  • Placebo comparator
    Placebo

    The study consists of sequential dosing cohorts, 8 subjects per cohort will be administered KH001 or placebo.

    Drug: Placebo

Interventions

  • DrugKH001

    The study drug is applied to teeth

  • DrugPlacebo

    The placebo is applied to teeth

06

What researchers measure

Primary outcomes

  1. Number of subjects with adverse events(AEs)

    The safety and tolerability of KH001 single and multiple ascending dose are evaluated. Adverse event(AE) is based on abnormal clinical laboratory tests, physical exam results and other medically assessments

    Time frame: up to 22 days and 36 days

Secondary outcomes

  1. Change from baseline in VAS(Visual Analogue Score).

    VAS scale (0-100mm)

    Time frame: up to 22 days and 36 days

  2. Maximum plasma concentration (Cmax) of KH001 single and multiple ascending dose.

    Pharmacokinetics parameter derived from plasma

    Time frame: 0~24 hours

  3. Area under the concentration-time curve (AUC) of KH001 single and multiple ascending dose

    Pharmacokinetics parameter derived from plasma

    Time frame: 0~24 hours

  4. Time to reach maximum concentration (Tmax) of KH001 single and multiple ascending dose

    Pharmacokinetics parameter derived from plasma

    Time frame: 0~24 hours

  5. Elimination half life (t½) of KH001 single and multiple ascending dose

    Pharmacokinetics parameter derived from plasma

    Time frame: 0~24 hours

  6. Estimate of apparent clearance (CL/F) of KH001 single and multiple ascending dose

    Pharmacokinetics parameter derived from plasma

    Time frame: 0~24 hours

  7. Change from Baseline in Evaporative Air Sensitivity and Tactile Threshold

    pain intensity assessed by 0-3 scale

    Time frame: up to 22 days and 36 days

  8. Change from baseline in Dentine Hypersensitivity Experience Questionnaire

    assessed by questionnaire

    Time frame: up to 22 days and 36 days

07

Study locations

1 site
  • Seoul National University Dental Hospital
    Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No — HysensBio Inc. will not be sharing individual de-identified participant data or other relevant study documents.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Mar 2023, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2021
First posted
Mar 18, 2021
StartActual
Jun 14, 2021
Primary completionActual
Mar 3, 2023
CompletionActual
Mar 3, 2023
Last update
Feb 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04804514
Lead sponsor
HysensBio Co., Ltd
Responsible party
Sponsor
First posted
Mar 18, 2021
Start date
Jun 14, 2021
Primary completion
Mar 3, 2023
Completion
Mar 3, 2023
Last update
Feb 26, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KH001

Start the discussion